AXP™ AutoXpress™ Platform - Next-Gen Technology to Maximize Your Baby’s Stem Cells

CryoCord Sdn. Bhd., Malaysia’s premier medical biotechnology company with an established presence in South East Asia, has securely preserved cord blood stem cells for more than 10,000 newborns throughout the region. Thousands of families have turned to CryoCord for its expertise, professionalism and integrity. In line with its drive for continuous excellence, CryoCord had adopted the next generation technology for the processing of cord blood stem cells, the AXP™ AutoXpress™ Platform.

The AXP™ AutoXpress™ Platform is a functionally-closed, automated, sterile system that consistently and efficiently harvests the priceless stem cells from umbilical cord blood.” The AXP™ AutoXpress™ Platform is designed to capture essential data for quality as surance and compliance with both international cGTP and cGMP standards, and offers consistently high recoveries of stem cells from cord blood (> 97% recovery rate).**

High cell recovery will translate to a higher cell count with an excellent chance of increased cell viability. With the AXP™ AutoXpress™ Platform, as well as the strategic partnership between CryoCord, GE Healthcare and Thermogenesis, CryoCord will be able to en sure the finest quality in the handling of its clients cord blood stem cells.

** Data provided by New York Blood Center